ZLAB - Encouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New Indications | Benzinga
Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) released topline data from the Phase 3 innovaTV 301 global trial in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy who received Tivdak (tisotumab vedotin-tftv), compared with chemotherapy alone.
The study met its primary endpoint of overall survival (OS).
An Independent Data Monitoring Committee determined that OS crossed the pre-specified efficacy boundary at interim analysis.
The key secondary endpoints of investigator-assessed progression-free survival and objective response rate also demonstrated statistical significance.
The results from innovaTV ...